Valeant (VRX)

See the following -

Mylan Isn't Alone: 11 Drugmakers with Off-the-Charts Pricing Power

Matt Krantz | USA Today | August 25, 2016

Mylan (MYL) is drawing fire for passing off massive price hikes for its EpiPen allergy treatment. But it’s far from being the drug company with the most pricing power. Gilead (GILD), Biogen (BIIB) and Amgen (AMGN), along with eight other drug giants in the Standard & Poor's 500, enjoyed off-the-charts pricing power on their products relative to costs — far beyond Mylan's, according to a USA TODAY analysis of data from S&P Global Market Intelligence...

Read More »